TY - JOUR
T1 - Duration of anxiety disorder and its associated risk indicators
T2 - Results of a longitudinal study of the general population
AU - ten Have, Margreet
AU - Tuithof, Marlous
AU - van Dorsselaer, Saskia
AU - Kleinjan, Marloes
AU - Penninx, Brenda W.J.H.
AU - Batelaan, Neeltje M.
AU - de Graaf, Ron
N1 - Funding Information: The Netherlands Mental Health Survey and Incidence Study-2 (NEMESIS-2) is conducted by the Netherlands Institute of Mental Health and Addiction (Trimbos Institute) in Utrecht. Financial support has been received from the Ministry of Health, Welfare and Sport, with supplementary support from the Netherlands Organization for Health Research and Development (ZonMw) and the Genetic Risk and Outcome of Psychosis (GROUP) investigators. The funding sources had no further role in study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the study for publication. Funding Information: The Netherlands Mental Health Survey and Incidence Study‐2 (NEMESIS‐2) is conducted by the Netherlands Institute of Mental Health and Addiction (Trimbos Institute) in Utrecht. Financial support has been received from the Ministry of Health, Welfare and Sport, with supplementary support from the Netherlands Organization for Health Research and Development (ZonMw) and the Genetic Risk and Outcome of Psychosis (GROUP) investigators. The funding sources had no further role in study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the study for publication. Publisher Copyright: © 2020 Wiley Periodicals LLC
PY - 2021/3
Y1 - 2021/3
N2 - Background: Data on episode duration of anxiety disorders are required for informing patients and for disease management, but such data from population studies are lacking. Methods: Three-year longitudinal data were used from the Netherlands Mental Health Survey and Incidence Study-2, a psychiatric epidemiological cohort study among the general adult population (N = 6646). Respondents with a new (first or recurrent) anxiety disorder were selected (n = 158). DSM-IV diagnoses were assessed with the Composite International Diagnostic Interview; the Life Chart Interview assessed episode duration and recovery rates. Results: Among those with anxiety disorder, median episode duration was 7.5 months and mean duration was 15.2 months. 38.8% had not recovered at 12 months and 30.1% not at 36 months. Longer duration was associated with older age, not having a paid job, higher neuroticism, more physical disorders, and worse physical functioning. Conclusions: Also, in the general population, anxiety disorder has a rather chronic course. After 12 months the cumulative recovery rate flattened. To prevent and manage chronicity, timely treatment, and chronic disease management are required. The risk indicators found may help to identify individuals with an anxiety disorder at risk for chronicity.
AB - Background: Data on episode duration of anxiety disorders are required for informing patients and for disease management, but such data from population studies are lacking. Methods: Three-year longitudinal data were used from the Netherlands Mental Health Survey and Incidence Study-2, a psychiatric epidemiological cohort study among the general adult population (N = 6646). Respondents with a new (first or recurrent) anxiety disorder were selected (n = 158). DSM-IV diagnoses were assessed with the Composite International Diagnostic Interview; the Life Chart Interview assessed episode duration and recovery rates. Results: Among those with anxiety disorder, median episode duration was 7.5 months and mean duration was 15.2 months. 38.8% had not recovered at 12 months and 30.1% not at 36 months. Longer duration was associated with older age, not having a paid job, higher neuroticism, more physical disorders, and worse physical functioning. Conclusions: Also, in the general population, anxiety disorder has a rather chronic course. After 12 months the cumulative recovery rate flattened. To prevent and manage chronicity, timely treatment, and chronic disease management are required. The risk indicators found may help to identify individuals with an anxiety disorder at risk for chronicity.
KW - anxiety disorder
KW - new episode
KW - population surveys
KW - risk factors
UR - http://www.scopus.com/inward/record.url?scp=85093915784&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/da.23103
DO - https://doi.org/10.1002/da.23103
M3 - Article
C2 - 33107675
SN - 1091-4269
VL - 38
SP - 328
EP - 336
JO - Depression and Anxiety
JF - Depression and Anxiety
IS - 3
ER -